Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

INTRODUCTION: In a 52-week, phase 3 clinical trial (LIBERTY AD CHRONOS) in adult patients with moderate-to-severe atopic dermatitis (AD), dupilumab in combination with topical corticosteroids (TCS) resulted in a significant improvement in overall Eczema Area and Severity Index (EASI) compared with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, de Bruin-Weller, Marjolein, Simpson, Eric L., Chen, Zhen, Zhang, Annie, Shumel, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776906/
https://www.ncbi.nlm.nih.gov/pubmed/34806137
http://dx.doi.org/10.1007/s13555-021-00638-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776906/
https://www.ncbi.nlm.nih.gov/pubmed/34806137
http://dx.doi.org/10.1007/s13555-021-00638-1

Ejemplares similares